Cancer With A High Tumor Mutational Burden clinical trials at UCSF

1 research study open to eligible people

Cancer with a high tumor mutational burden has many genetic changes. UCSF is testing a new IL-2 immunotherapy treatment to check its safety and effectiveness. This trial is in its first and second phases and includes several study locations.

Showing trials for

  • Beta-only IL-2 ImmunoTherapY Study

    open to eligible people ages 18 years and up

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    San Francisco, California and other locations

Last updated: